Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Withdrawal because of adverse effects
[64] Systematic review	Number of people and RCTs in analysis not clear	Proportion of people permanently discontinuing study medication, primarily owing to adverse effects 2 years 41% with amiodarone 27% with placebo Absolute numbers not reported
Adverse effects
[64] Systematic review	Number of people in analysis not clear 10 RCTs in this analysis	Odds of reporting adverse drug reactions with amiodarone with placebo Absolute results not reported	OR 2.22 95% CI 1.83 to 2.68	Moderate effect size	placebo
[64] Systematic review	Number of people and RCTs in analysis not clear	Proportion of people reporting hypothyroidism 7% with amiodarone 1% with placebo Absolute numbers not reported
[64] Systematic review	Number of people and RCTs in analysis not clear	Proportion of people with hyperthyroidism 1.4% with amiodarone 0.5% with placebo Absolute numbers not reported
[64] Systematic review	Number of people and RCTs in analysis not clear	Proportion of people with peripheral neuropathy 0.5% with amiodarone 0.2% with placebo Absolute numbers not reported
[64] Systematic review	Number of people and RCTs in analysis not clear	Proportion of people with lung infiltrates 2% with amiodarone 1% with placebo Absolute numbers not reported
[64] Systematic review	Number of people and RCTs in analysis not clear	Proportion of people with bradycardia 2% with amiodarone 1% with placebo Absolute numbers not reported
[64] Systematic review	Number of people and RCTs in analysis not clear	Proportion of people with liver dysfunction 1% with amiodarone 0.4% with placebo Absolute numbers not reported